YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
[US Food and Drug Administration (FDA)] Teva Pharmaceutical (TEVA [https://seekingalpha.com/symbol/TEVA]) and its European partner Medincell (MDCLF [https://seekingalpha.com/symbol/MDCLF]) announced that the FDA has accepted their marketin…
OLANZAPINE LAI: EU Submission Expected in Q2 2026 MONTPELLIER, France, January 28, 2026--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner, Teva Pharmaceuticals, today shared the following information in connection with t…
As European markets navigate renewed trade and geopolitical uncertainties, with major indices like the STOXX Europe 600 Index ending lower, investors are increasingly focusing on insider ownership as a potential indicator of company confid…
As the European market edges closer to record highs, driven by positive sentiment around earnings and economic prospects for the coming year, investors are increasingly focusing on growth stocks with substantial insider ownership. In this…
(April 1st, 2025 - September 30, 2025) MONTPELLIER, France, December 09, 2025--(BUSINESS WIRE)--Regulatory News: Christophe Douat, CEO of Medincell (Paris:MEDCL): "We are pleased with the company’s growth and momentum. We have entered the…
MONTPELLIER, France, December 09, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, f…
As European markets show resilience with the STOXX Europe 600 Index climbing 2.35% and major single-country indexes also advancing, investors are closely monitoring inflation trends that suggest eurozone inflation could remain near the ECB…
MONTPELLIER, France, November 05, 2025--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About Olanzapine Long-Acting Injectable (TEV-749 / mdc-TJK) 1-Month su…
As European markets experience a notable upswing, with the STOXX Europe 600 Index climbing 1.68% and major indices across Germany, Italy, France, and the UK showing positive momentum, investors are increasingly focused on growth opportunit…
FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.1 UZEDY (risperidon…
Teva Pharmaceutical Industries Ltd FDA approves UZEDY® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I dis…
As European markets remain steady with the pan-European STOXX Europe 600 Index ending little changed, investors are keenly observing interest rate policies and trade dynamics that continue to influence sentiment. In this environment, compa…
MONTPELLIER, France, September 23, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Teva Canada Limited, a subsidiary of Medincell’s partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperid…
UZEDY® was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna® (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization More Healthcare Practitioners (HCPs…
There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell’s Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The long-term systemic safety profile was consiste…
MONTPELLIER, France, September 17, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 2…
MONTPELLIER, France, September 12, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Char…
Amidst a backdrop of political instability in France and renewed tariff uncertainties, the European market has experienced a downturn, with major indices such as the STOXX Europe 600 Index seeing notable declines. In this environment, grow…
MONTPELLIER, France, July 30, 2025--(BUSINESS WIRE)--Regulatory News: Medincell’s (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information: About UZEDY® 1-Month and 2-Month subcutaneous risperidone for schizophreni…
MONTPELLIER, France, July 29, 2025--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, aCNS-focused biotech that developed the successful dr…
As European markets show tentative optimism with the pan-European STOXX Europe 600 Index rising by 0.54%, the focus remains on potential trade deals between the EU and U.S., which are bolstering investor sentiment. In this environment, gro…
As the European markets navigate a landscape marked by geopolitical tensions and economic adjustments, indices like the STOXX Europe 600 have experienced declines amid concerns over Middle East unrest. In this environment, growth companies…
As European markets experience a boost in sentiment following the de-escalation of U.S.-China trade tensions, major indices such as the STOXX Europe 600 have shown positive performance. In this context, identifying stocks that are potentia…
As trade tensions between the U.S. and China show signs of easing, European markets have responded positively, with major indices like Germany's DAX and France's CAC 40 seeing notable gains. Against this backdrop of cautious optimism, inve…
MONTPELLIER, France, August 02, 2023--(BUSINESS WIRE)--MedinCell (Paris:MEDCL): Access here the complete press release During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President,…
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The drawdown of this last tranche of a 40 million euros total loan signed with the EIB in November 2022 was conditioned by US FDA's approval of…
MONTPELLIER, France, July 31, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): The 2022-23 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the re…
PARIS, July 07, 2023--(BUSINESS WIRE)--Regulatory News: Under the liquidity contract entered into between MEDINCELL (Paris:MEDCL) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023: 31,431 sha…
April 2022 - March 2023 MONTPELLIER, France, June 26, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): 2022-23 Highlights Launch of UZEDY™, first commercial product based on BEPO® technology in May 2023 (post-closing) Succe…
MONTPELLIER, France, June 20, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL) will hold a videoconference on Monday June 26, 2023 at 6:30 pm to present the 2022-2023 annual results for the year ending on March 31st, 2023. >…
MONTPELLIER, France, June 05, 2023--(BUSINESS WIRE)--Regulatory News: Due to operational imperatives, the publication of annual results for the year ending March 31, 2023, originally scheduled for June 13th, has been postponed to June 26th…
mdc-TJK has the potential to be the first long-acting injectable of olanzapine with a favorable safety profile MedinCell’s partner, Teva Pharmaceuticals, highlighted mdc-TJK as one of their three promising late-stage assets poised to accel…
Successful Private Placement allowing to reach a total amount of €25 million Strong financial position to continue portfolio development and strengthen R&D activities New cash visibility until at least Q4 2025 MONTPELLIER, France, May 12,…
THIS PRESS RELEASE IS NOT BEING MADE IN AND COPIES OF IT MAY NOT BE DISTRIBUTED OR SENT, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA MONTPELLIER, France, May 11, 2023--(BUSINESS WIRE)--Regulator…
MONTPELLIER, France, May 04, 2023--(BUSINESS WIRE)--Regulatory News: MedinCell (Paris:MEDCL): An original presentation describing pharmacokinetic characteristics of an investigational long-acting subcutaneous formulation of olanzapine (mdc…
MedinCell will hold a video conference for its shareholders and the financial community on May 2nd, 2023 6:30pm CEST in French, to connect: www.medincell.com/fr/investisseurs/#events 7:30pm CEST in English, to connect: www.medincell.com/en…